Suppr超能文献

冈比亚结核病患者治疗后ELISPOT检测结果的逆转

Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases.

作者信息

Aiken Alexander M, Hill Philip C, Fox Annette, McAdam Keith P W J, Jackson-Sillah Dolly, Lugos Moses D, Donkor Simon A, Adegbola Richard A, Brookes Roger H

机构信息

Tuberculosis Division, Medical Research Council Laboratories, Banjul, The Gambia.

出版信息

BMC Infect Dis. 2006 Mar 30;6:66. doi: 10.1186/1471-2334-6-66.

Abstract

BACKGROUND

New tools are required to improve tuberculosis (TB) diagnosis and treatment, including enhanced ability to compare new treatment strategies. The ELISPOT assay uses Mycobacterium tuberculosis-specific antigens to produce a precise quantitative readout of the immune response to pathogen. We hypothesized that TB patients in The Gambia would have reduced ELISPOT counts after successful treatment.

METHODS

We recruited Gambian adults with sputum smear and culture positive tuberculosis for ELISPOT assay and HIV test, and followed them up one year later to repeat testing and document treatment outcome. We used ESAT-6, CFP-10 and Purified Protein Derivative (PPD) as stimulatory antigens. We confirmed the reliability of our assay in 23 volunteers through 2 tests one week apart, comparing within and between subject variation.

RESULTS

We performed an ELISPOT test at diagnosis and 12 months later in 89 patients. At recruitment, 70/85 HIV-negative patients (82%) were ESAT-6 or CFP-10 (EC) ELISPOT positive, 77 (90%) were PPD ELISPOT positive. Eighty-two cases (96%) successfully completed treatment: 44 (55%; p < 0.001) were EC ELISPOT negative at 12 months, 17 (21%; p = 0.051) were PPD ELISPOT negative. Sixty (73%) cured cases had a CFP-10 ELISPOT count decrease, 64 (78%) had an ESAT-6 ELISPOT count decrease, 58 (70%) had a PPD ELISPOT count decrease. There was a mean decline of 25, 44 and 47 SFU/2 x 105 cells for CFP-10, ESAT-6 and PPD respectively (p < 0.001 for all). Three of 4 HIV positive patients were cured, all 3 underwent ELISPOT reversion; all 4 not cured subjects (3 HIV-negative, 1 HIV positive) were ESAT-6, CFP-10 and PPD ELISPOT positive at 12 months.

CONCLUSION

Successful tuberculosis treatment is accompanied by a significant reduction in the M. tuberculosis-specific antigen ELISPOT count. The ELISPOT has potential as a proxy measure of TB treatment outcome. Further investigation into the decay kinetics of T-cells with treatment is warranted.

摘要

背景

需要新的工具来改善结核病(TB)的诊断和治疗,包括增强比较新治疗策略的能力。酶联免疫斑点(ELISPOT)检测使用结核分枝杆菌特异性抗原对病原体的免疫反应进行精确的定量分析。我们推测冈比亚的结核病患者在成功治疗后ELISPOT计数会降低。

方法

我们招募了痰涂片和培养阳性的冈比亚成年结核病患者进行ELISPOT检测和HIV检测,并在一年后对他们进行随访,以重复检测并记录治疗结果。我们使用早期分泌性抗原靶6(ESAT-6)、培养滤液蛋白10(CFP-10)和纯化蛋白衍生物(PPD)作为刺激抗原。我们通过间隔一周的两次检测,比较受试者内部和之间的差异,在23名志愿者中确认了我们检测方法的可靠性。

结果

我们对89例患者在诊断时和12个月后进行了ELISPOT检测。在招募时,85例HIV阴性患者中有70例(82%)ESAT-6或CFP-10(EC)ELISPOT检测呈阳性,77例(90%)PPD ELISPOT检测呈阳性。82例(96%)成功完成治疗:44例(55%;p<0.001)在12个月时EC ELISPOT检测为阴性,17例(21%;p=0.051)PPD ELISPOT检测为阴性。60例(73%)治愈病例的CFP-10 ELISPOT计数下降,64例(78%)ESAT-6 ELISPOT计数下降,58例(70%)PPD ELISPOT计数下降。CFP-10、ESAT-6和PPD的每2×105个细胞的斑点形成单位(SFU)平均分别下降25、44和47(所有p<0.001)。4例HIV阳性患者中有3例治愈,所有3例ELISPOT检测结果逆转;所有4例未治愈的受试者(3例HIV阴性,1例HIV阳性)在12个月时ESAT-6、CFP-10和PPD ELISPOT检测均为阳性。

结论

成功的结核病治疗伴随着结核分枝杆菌特异性抗原ELISPOT计数的显著降低。ELISPOT检测有潜力作为结核病治疗结果的替代指标。有必要进一步研究治疗过程中T细胞的衰减动力学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b17e/1562425/6bb36e2be684/1471-2334-6-66-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验